{"id":"W3089112078","doi":"10.1016/j.annonc.2020.08.870","title":"610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Meso Scale Diagnostics; AstraZeneca","keywords":"Olaparib; Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Population; Oncology; Cohort; Progression-free survival; Randomized controlled trial; Urology; Cancer; Chemotherapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008456695,0.0003189596,0.0007062986,0.0002519678,0.0001990248,0.000734408,0.0002991009,0.0004794053,0.004254635],"category_scores_gemma":[0.001610693,0.0001423766,0.00166578,0.000293981,0.0003339553,0.0007441542,0.0004017283,0.001017106,0.000249157],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006104399,"about_ca_system_score_gemma":0.0005748078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001223435,"about_ca_topic_score_gemma":0.002990814,"domain_scores_codex":[0.999566,0.0001425321,0.00002647308,0.0001074468,0.0000404678,0.0001169842],"domain_scores_gemma":[0.9992102,0.000371182,0.0001149416,0.00002896779,0.00003274065,0.0002418458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6338326,0.003026506,0.2604273,0.0004414255,0.002920609,0.0003606048,0.0002393529,0.006481797,0.005801115,0.0005248563,0.002698677,0.08324519],"study_design_scores_gemma":[0.02131371,0.1899437,0.7495803,0.0002093107,0.007298837,0.001040011,0.00111776,0.01633892,0.003985537,0.001955681,0.007060388,0.0001558784],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997174,0.0007502406,0.000137663,0.0001170386,0.00004883643,0.00002215471,0.0004305688,0.000006687335,0.001312724],"genre_scores_gemma":[0.9987601,0.0001582497,0.00007401491,0.00008300084,0.00004035893,0.00001576017,0.0004704699,0.000002586357,0.0003955548],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004254635,"threshold_uncertainty_score":0.01423317,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1253569742110233,"score_gpt":0.3941244951630284,"score_spread":0.2687675209520051,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}